ArticleMaterials today. Bio2025
Harnessing hollow Prussian blue nanozymes for efficient photothermal lithotripsy while protecting the kidneys from oxidative stress injury.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Herba Lysimachiae Polysaccharide-Modified Selenium Nanoparticles Alleviate Oxidative Injury in Kidney Stones via TOMM22-Regulated Mitophagy Activation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Visibly Transparent, Near-Infrared Absorbing Nanofluids Enable High-Efficiency and Safe Laser Lithotripsy.bioRxiv : the preprint server for biology · 2026Article
- The Application of Nanomaterials in Kidney Stone Disease: Emerging Strategies for Early Diagnosis, Targeted Therapy, and Prevention.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney stones, given the high incidence and recurrence rates, pose a critical challenge to public health. High-power laser lithotripsy may induce damage to renal tissues, while existing therapeutic drugs have limitations in relieving the damage to renal tubular epithelial cells induced by oxidative stress. This injury promotes crystal aggregation and adhesion, further exacerbating cell damage and forming a vicious cycle. To address this problem, we proposed hollow Prussian blue (HPB) nanozymes for efficient photothermal lithotripsy while protecting the kidneys from oxidative stress injury. The in vitro lithotripsy results demonstrate that the efficiency of lithotripsy could be enhanced by adhering HPB to the surface of kidney stones thanks to its photothermal effect and stability characteristic under low power 808 nm near-infrared laser. No significant renal tissue damage was observed after the procedure, indicating its safety. In vitro HPB can simulate the activities of various antioxidant enzymes, thereby scavenge free radicals and protect cells from oxidative stress damage. Meanwhile, an animal model of renal CaOx crystals induced by glyoxylate was established to explore the safety and therapeutic effect of HPB. HPB could scavenge reactive oxygen species (ROS) and attenuate oxidative stress through its excellent biocompatibility and antioxidant enzyme activity, which protects renal tubular cells, upregulates the expression of antioxidant enzymes, downregulates proteins associated with stone adhesion and renal injury, and ultimately inhibits crystal deposition. Collectively, HPB not only provides an experimental theoretical foundation for novel lithotripsy techniques but also offers new insights into kidney protection and the prevention of crystal deposition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.